Neurol. praxi. 2024;25(3):198-202 | DOI: 10.36290/neu.2024.026

New­‑onset refractory status epilepticus

MUDr. Michaela Nová, doc. MUDr. Zdeněk Vojtěch, Ph.D., MBA
Centrum pro epilepsie, Nemocnice Na Homolce, Praha

New-onset refraktory status epilepticus (NORSE) is a rare severe condition with possible fatal consequences. Etiology of the syndrome often remains unclear. The term NORSE describes the clinical condition according to patient's symptoms and history but has no connection with a specific etiology. Achievement of the control of seizures is our main priority in management of every status epilepticus (SE), however finding the etiology of SE has both therapeutic and prognostic implications. Aim of this article is to suggest diagnostic and therapeutic processes based on the considered/confirmed underlying cause of NORSE.

Keywords: new­‑onset refractory status epilepticus, cryptogenic NORSE, autoimmune encephalitis, corticosteroids, immunotherapy, ketogenic diet.

Received: March 11, 2024; Revised: April 15, 2024; Accepted: April 15, 2024; Prepublished online: April 15, 2024; Published: June 20, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Nová M, Vojtěch Z. New­‑onset refractory status epilepticus. Neurol. praxi. 2024;25(3):198-202. doi: 10.36290/neu.2024.026.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Cabezudo­‑García P, Mena­‑Vázquez N, Villagrán­‑García M, et al. Efficacy of antiepileptic drugs in autoimmune epilepsy: A systematic review. Seizure. 2018;59:72-76. doi: 10.1016/j.seizure.2018. 05. 004. Go to original source...
    2. Caraballo RH, Reyes G, Avaria MF, et al. Febrile infection­‑related epilepsy syndrome: a study of 12 patients. Seizure. 2013;22(7):553-9. doi: 10.1016/j.seizure.2013. 04. 005. Go to original source...
    3. Dilena R, Mauri E, Aronica E, et al. Therapeutic effect of Anakinra in the relapsing chronic phase of febrile infection­‑related epilepsy syndrome. Epilepsia Open. 2019;4(2):344-350. doi: 10.1002/epi4.12317. Go to original source... Go to PubMed...
    4. Eyre M, Hacohen Y, Lamb K, et al. Utility and safety of plasma exchange in paediatric neuroimmune disorders. Dev Med Child Neurol. 2019;61(5):540-546. doi: 10.1111/dmcn.14150. Go to original source... Go to PubMed...
    5. Gaspard N, Foreman BP, Alvarez V, et al. Critical Care EEG Monitoring Research Consortium (CCEMRC). New­‑onset refractory status epilepticus: Etiology, clinical features, and outcome. Neurology. 2015;85(18):1604-13. doi: 10.1212/WNL.0000000000001940. Go to original source... Go to PubMed...
    6. Gaspard N, Hirsch LJ, Sculier C, et al. New­‑onset refractory status epilepticus (NORSE) and febrile infection­‑related epilepsy syndrome (FIRES): State of the art and perspectives. Epilepsia. 2018;59(4):745-752. doi: 10.1111/epi.14022. Go to original source... Go to PubMed...
    7. Gaspard N. Unusual causes of status epilepticus. Status epilepticus. Springer, Cham. 2018:87-110. doi: 10.1007/978-3-319-58200-9_8. Go to original source...
    8. Hirsch LJ, Gaspard N, van Baalen A, et al. Proposed consensus definitions for new­‑onset refractory status epilepticus (NORSE), febrile infection­‑related epilepsy syndrome (FIRES), and related conditions. Epilepsia. 2018;59(4):739-744. doi: 10.1111/epi.14016. Go to original source... Go to PubMed...
    9. Hirsch LJ, Gaspard N. Status epilepticus. Continuum (Minneap Minn). 2013;19(3 Epilepsy):767-94. doi: 10.1212/01.CON.0000431395.16229.5a. Go to original source... Go to PubMed...
    10. Iizuka T, Kanazawa N, et al. Cryptogenic NORSE: Its distinctive clinical features and response to immunotherapy. Neurol Neuroimmunol Neuroinflamm. 2017;4(6):e396. doi: 10.1212/NXI.0000000000000396. Go to original source... Go to PubMed...
    11. Kessi M, Liu F, Zhan Y, et al. Efficacy of different treatment modalities for acute and chronic phases of the febrile infection­‑related epilepsy syndrome: A systematic review. Seizure. 2020;79:61-68. doi: 10.1016/j.seizure.2020. 04. 015. Go to original source...
    12. Körtvelyessy P, Lerche H, Weber Y. FIRES and NORSE are distinct entities. Epilepsia. 2012;53(7):1276. doi: 10.1111/j.1528-1167.2012.03517.x. Go to original source... Go to PubMed...
    13. Kramer U, Chi CS, Lin KL, et al. Febrile infection­‑related epilepsy syndrome (FIRES): pathogenesis, treatment, and outcome: a multicenter study on 77 children. Epilepsia. 2011;52(11):1956-65. doi: 10.1111/j.1528-1167.2011.03250.x. Go to original source... Go to PubMed...
    14. Luo T, Wang Y, Lu G, et al. Vagus nerve stimulation for super­‑refractory status epilepticus in febrile infection­‑related epilepsy syndrome: a pediatric case report and literature review. Childs Nerv Syst. 2022 Jul;38(7):1401-1404. doi: 10.1007/s00381-021-05410-6. Go to original source... Go to PubMed...
    15. Meletti S, Slonkova J, Mareckova I, et al. Claustrum damage and refractory status epilepticus following febrile illness. Neurology. 2015;85(14):1224-32. doi: 10.1212/WNL.0000000000001996. Go to original source... Go to PubMed...
    16. Meletti S, Giovannini G, d'Orsi G, et al. New­‑Onset Refractory Status Epilepticus with Claustrum Damage: Definition of the Clinical and Neuroimaging Features. Front Neurol. 2017;8:111. doi: 10.3389/fneur.2017.00111. Go to original source... Go to PubMed...
    17. Mikaeloff Y, Jambaqué I, Hertz­‑Pannier L, et al. Devastating epileptic encephalopathy in school­‑aged children (DESC): a pseudo encephalitis. Epilepsy Res. 2006;69(1):67-79. doi: 10.1016/j.eplepsyres.2006. 01. 002. Go to original source...
    18. Nabbout R, Vezzani A, Dulac O, Chiron C. Acute encephalopathy with inflammation­‑mediated status epilepticus. Lancet Neurol. 2011;10(1):99-108. doi: 10.1016/S1474-4422(10)70214-3. Go to original source... Go to PubMed...
    19. Nabbout R. FIRES and IHHE: Delineation of the syndromes. Epilepsia. 2013;54(Suppl. 6):54-6. doi: 10.1111/epi.12278. Go to original source... Go to PubMed...
    20. Sakuma H, Tanuma N, Kuki I, et al. Intrathecal overproduction of proinflammatory cytokines and chemokines in febrile infection­‑related refractory status epilepticus. J Neurol Neurosurg Psychiatry. 2015;86(7):820-2. doi: 10.1136/jnnp-2014-309388. Go to original source... Go to PubMed...
    21. Sato Y, Numata­‑Uematsu Y, Uematsu M, et al. Acute encephalitis with refractory, repetitive partial seizures: Pathological findings and a new therapeutic approach using tacrolimus. Brain Dev. 2016;38(8):772-6. doi: 10.1016/j.braindev.2016. 02. 006. Go to original source...
    22. Sculier C, Gaspard N. New onset refractory status epilepticus (NORSE). Seizure. 2019;68:72-78. doi: 10.1016/j.seizure.2018. 09. 018. Go to original source...
    23. Sutter R, Marsch S, Fuhr P, et al. Anesthetic drugs in status epilepticus: risk or rescue? A 6-year cohort study. Neurology. 2014;82(8):656-64. doi: 10.1212/WNL.0000000000000009. Go to original source... Go to PubMed...
    24. Thakur KT, Probasco JC, Hocker SE, et al. Ketogenic diet for adults in super­‑refractory status epilepticus. Neurology. 2014;82(8):665-70. doi: 10.1212/WNL.0000000000000151. Go to original source... Go to PubMed...
    25. Titulaer MJ, McCracken L, Gabilondo I, et al. Treatment and prognostic factors for long­‑term outcome in patients with anti­‑NMDA receptor encephalitis: an observational cohort study. Lancet Neurol. 2013;12(2):157-65. doi: 10.1016/S1474-4422(12)70310-1. Go to original source... Go to PubMed...
    26. Trinka E, Leitinger M. Management of Status Epilepticus, Refractory Status Epilepticus, and Super­‑refractory Status Epilepticus. Continuum (Minneap Minn). 2022;28(2):559-602. doi: 10.1212/CON.0000000000001103. Go to original source... Go to PubMed...
    27. van Baalen A, Vezzani A, Häusler M, et al. Febrile Infection­‑Related Epilepsy Syndrome: Clinical Review and Hypotheses of Epileptogenesis. Neuropediatrics. 2017;48(1):5-18. doi: 10.1055/s-0036-1597271. Go to original source... Go to PubMed...
    28. Wickstrom R, Taraschenko O, Dilena R, et al; International NORSE Consensus Group. International consensus recommendations for management of New Onset Refractory Status Epilepticus (NORSE) incl. Febrile Infection­‑Related Epilepsy Syndrome (FIRES): Statements and Supporting Evidence. Epilepsia. 2022;63(11):2840-64. doi: 10.1111/epi.17397. Go to original source... Go to PubMed...
    29. Wilder­‑Smith EP, Lim EC, Teoh HL, et al. The NORSE (new­‑onset refractory status epilepticus) syndrome: defining a disease entity. Ann Acad Med Singap. 2005;34(7):417-20. Go to original source...
    30. Yamazoe T, Okanishi T, Yamamoto A, et al. New­‑onset refractory status epilepticus treated with vagus nerve stimulation: A case report. Seizure. 2017;47:1-4. doi: 10.1016/j.seizure.2017. 02. 011. Go to original source...

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.